Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | PLoS Medicine | 2009 | 37.9K |
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials | BMJ, The | 2011 | 16K |
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | BMJ, The | 2009 | 13.3K |
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration | BMJ, The | 2009 | 9.7K |
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration | PLoS Medicine | 2009 | 9.1K |
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls | Nature | 2007 | 7.8K |
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Journal of Clinical Epidemiology | 2009 | 7.7K |
Analysis of protein-coding genetic variation in 60,706 humans | Nature | 2016 | 6.9K |
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | International Journal of Surgery | 2010 | 6.6K |
The variant call format and VCFtools | Bioinformatics | 2011 | 6.2K |
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration | Journal of Clinical Epidemiology | 2009 | 6.1K |
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation | BMJ, The | 2015 | 5.8K |
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study | BMJ: British Medical Journal | 2000 | 5.7K |
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies | Journal of Clinical Epidemiology | 2008 | 4.8K |
Dexamethasone in Hospitalized Patients with Covid-19 | New England Journal of Medicine | 2021 | 4.4K |
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions | BMJ, The | 2016 | 4.4K |
Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research | PLoS Biology | 2010 | 4.2K |
CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials | BMJ, The | 2010 | 4.2K |
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) | Autophagy | 2016 | 3.8K |
RoB 2: a revised tool for assessing risk of bias in randomised trials | BMJ, The | 2019 | 3.8K |
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes | New England Journal of Medicine | 2017 | 3.8K |
A novel coronavirus outbreak of global health concern | Lancet, The | 2020 | 3.7K |
Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines | Journal of Extracellular Vesicles | 2018 | 3.6K |
Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide | BMJ, The | 2014 | 3.6K |
ABC transporters: from microorganisms to man | Annual Review of Cell Biology | 1992 | 3.3K |